<DOC>
	<DOCNO>NCT00975221</DOCNO>
	<brief_summary>This study design demonstrate efficacy assess safety cinacalcet reduction hypercalcemia patient primary hyperparathyroidism parathyroidectomy indicated basis elevate correct total serum calcium , unable undergo parathyroidectomy .</brief_summary>
	<brief_title>Efficacy Safety Study Cinacalcet Treatment Hypercalcemia Patients With Primary Hyperparathyroidism Unable Undergo Parathyroidectomy</brief_title>
	<detailed_description>The study consist 30-day screening phase , 12-week placebo-controlled dose-titration phase , 16-week placebo-controlled efficacy assessment phase ( EAP ) . Participants complete 28 week study continue open-label safety extension phase 24 week investigational cinacalcet treatment .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>age ≥ 18 year diagnosis primary hyperparathyroidism ( HPT ) subject must follow laboratory value : 1. local/historical laboratory result show correct total serum calcium &gt; 1 mg/dL ( 0.25 mmol/L ) upper limit normal ≤ 12.5 mg/dL ( 3.12 mmol/L ) within past 12 month , local/historical laboratory result show plasma parathyroid horone ( PTH ) &gt; 75 % upper limit normal within past 12 month , one central laboratory draw screen visit show correct total serum calcium &gt; 11.3 mg/dL ( 2.82 mmol/L ) ≤ 12.5 mg/dL ( 3.12 mmol/L ) , one central laboratory draw screen visit show plasma PTH &gt; 55 pg/mL ( 5.8 pmol/L ) OR 2. two central laboratory draw perform screening period least 7 day apart , show correct total serum calcium &gt; 11.3 mg/dL ( 2.82 mmol/L ) ≤ 12.5 mg/dL ( 3.12 mmol/L ) , plasma PTH &gt; 55 pg/mL ( 5.8 pmol/L ) able undergo parathyroidectomy ≥ 1 follow reason : fail parathyroidectomy comorbid condition contraindicate parathyroidectomy parathyroidectomy consider appropriate feasible primary physician subject studyspecific procedure perform , appropriate write informed consent must obtain symptom attributable hypercalcemia , require immediate medical intervention , judge investigator ( include acute kidney stone , nausea vomit require intravenous hydration , confusion , lethargy , stupor , coma ) unstable medical condition , define hospitalize within 30 day date inform consent , otherwise unstable judgment investigator administration drug increase serum calcium concentration , include limited thiazide diuretic lithium initiate bisphosphonate therapy change bisphosphonate dose within 12 week date inform consent current administration drug ventricular arrhythmia unable provide inform consent , risk poor compliance study procedure currently enrol another investigational device drug study ( ) , complete study within 30 day date informed consent know hypersensitivity unable tolerate cinacalcet receive treatment cinacalcet within 60 day date informed consent history seizure adjustment antiseizure medication within 12 week date inform consent family history diagnosis genetic syndrome , familial benign hypocalciuric hypercalcemia ( FBHH ) multiple endocrine neoplasia type 1 ( MEN1 ) type 2 ( MEN2 ) , primary HPT one clinical manifestation familial benign hypocalciuric hypercalcemia ( FBHH ) refuse use highly effective contraceptive measure ( determine investigator ) throughout study pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Primary hyperparathyroidism</keyword>
	<keyword>Parathyroidectomy</keyword>
	<keyword>Hypercalcemia</keyword>
</DOC>